

# George W Sledge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7322696/publications.pdf>

Version: 2024-02-01

94  
papers

8,626  
citations

159585

30  
h-index

66911

78  
g-index

96  
all docs

96  
docs citations

96  
times ranked

11887  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). <i>Journal of Clinical Oncology</i> , 2022, 40, 978-987.  | 1.6  | 86        |
| 2  | Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.  | 7.0  | 35        |
| 3  | Patient perspectives on window of opportunity clinical trials in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, , 1.  | 2.5  | 0         |
| 4  | Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization.. <i>Journal of Clinical Oncology</i> , 2022, 40, 597-597.  | 1.6  | 0         |
| 5  | Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1112-TPS1112.                        | 1.6  | 0         |
| 6  | A case-control study of healthcare disparities in sex and gender minority patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6517-6517.  | 1.6  | 1         |
| 7  | Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12612-e12612.   | 1.6  | 0         |
| 8  | Optimal timing and interval of imaging for metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1106-1106.  | 1.6  | 0         |
| 9  | Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 604-615.  | 6.4  | 16        |
| 10 | Liquid biopsy enters the clinic – implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.   | 27.6 | 609       |
| 11 | Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. <i>Breast Cancer</i> , 2021, 28, 1038-1050.                           | 2.9  | 10        |
| 12 | Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 600-614.  | 2.1  | 5         |
| 13 | Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacicimab in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1988-1995.  | 4.1  | 6         |
| 14 | Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87.   | 5.0  | 21        |
| 15 | Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.  | 7.1  | 13        |
| 16 | MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2 <sup>+</sup> -Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5801-5809.  | 7.0  | 3         |
| 17 | Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. <i>Cell Chemical Biology</i> , 2021, 28, 1206-1220.e6.   | 5.2  | 19        |
| 18 | Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 417-428. | 2.5  | 20        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | The optimal duration of endocrine therapy in hormone receptor-positive breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 383-404.  | 0.3  | 0         |
| 20 | Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for <i>in Vivo</i> Multiplexing Studies. <i>Nano Letters</i> , 2020, 20, 101-108.  | 9.1  | 28        |
| 21 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy- MONARCH 2. <i>JAMA Oncology</i> , 2020, 6, 116.   | 7.1  | 572       |
| 22 | Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. <i>Oncologist</i> , 2020, 25, e243-e251.  | 3.7  | 45        |
| 23 | Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply. <i>JAMA Oncology</i> , 2020, 6, 1122.  | 7.1  | 10        |
| 24 | The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.   | 10.9 | 38        |
| 25 | MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1061-1061.   | 1.6  | 2         |
| 26 | Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7004-7004.  | 1.6  | 1         |
| 27 | A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA2-LBA2.                 | 1.6  | 85        |
| 28 | Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7063-7063.   | 1.6  | 0         |
| 29 | Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (Ols).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19314-e19314.  | 1.6  | 0         |
| 30 | Understanding patient perspectives on window of opportunity clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 181-181.  | 1.6  | 0         |
| 31 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions</i> . <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.  | 2.9  | 11        |
| 32 | Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. <i>JAMIA Open</i> , 2019, 2, 528-537.   | 2.0  | 40        |
| 33 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.  | 2.9  | 15        |
| 34 | Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 98.   | 5.0  | 31        |
| 35 | Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.   | 3.0  | 8         |
| 36 | Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. <i>Clinical Breast Cancer</i> , 2019, 19, 259-267.e1. | 2.4  | 22        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.  | 27.0 | 349       |
| 38 | Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods. <i>Nano Letters</i> , 2019, 19, 2334-2342.   | 9.1  | 17        |
| 39 | Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4769-4771.                                       | 7.1  | 6         |
| 40 | Patients and Physicians in the Era of Modern Cancer Care. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 829.   | 7.4  | 5         |
| 41 | Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. <i>Journal of Clinical Oncology</i> , 2019, 37, 503-503.         | 1.6  | 5         |
| 42 | Radiomics features to identify distinct subtypes of triple-negative breast cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 3069-3069.  | 1.6  | 0         |
| 43 | Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2851-2858.  | 7.0  | 65        |
| 44 | Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1003-1008.   | 6.3  | 19        |
| 45 | Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers. <i>Molecular Carcinogenesis</i> , 2018, 57, 567-575.  | 2.7  | 6         |
| 46 | Local Control of Distant Disease: Yes, but Where to Next?. <i>Journal of Oncology Practice</i> , 2018, 14, 357-358.   | 2.5  | 0         |
| 47 | Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). <i>Journal of Clinical Oncology</i> , 2018, 36, 2621-2629. | 1.6  | 52        |
| 48 | Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky062.   | 2.9  | 199       |
| 49 | Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.  | 7.1  | 151       |
| 50 | Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.   | 27.0 | 1,558     |
| 51 | Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1002-1002.   | 1.6  | 13        |
| 52 | Symptom burden and employment status in breast cancer (BC) survivors. <i>Journal of Clinical Oncology</i> , 2018, 36, 10073-10073.  | 1.6  | 3         |
| 53 | Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies. <i>Journal of Clinical Oncology</i> , 2018, 36, 1048-1048.                                      | 1.6  | 2         |
| 54 | Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 1049-1049.     | 1.6  | 8         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | The association of early toxicity and outcomes for patients treated with abemaciclib.. Journal of Clinical Oncology, 2018, 36, 1053-1053.  | 1.6  | 7         |
| 56 | TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.. Journal of Clinical Oncology, 2018, 36, LBA1-LBA1. | 1.6  | 11        |
| 57 | Urgent hypertension as a biomarker for bevacizumab in the curative setting.. Journal of Clinical Oncology, 2018, 36, 548-548.  | 1.6  | 0         |
| 58 | Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors. Psycho-Oncology, 2017, 26, 982-990.   | 2.3  | 27        |
| 59 | Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-“positive breast cancer: NCIC CTG MA.27. Cancer, 2017, 123, 2444-2451.   | 4.1  | 11        |
| 60 | Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical Cancer Research, 2017, 23, 43-51.   | 7.0  | 73        |
| 61 | Synergistic drug combinations from electronic health records and gene expression. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 565-576.   | 4.4  | 9         |
| 62 | Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Annals of Surgical Oncology, 2017, 24, 38-51.   | 1.5  | 80        |
| 63 | Put Some PEPI in Your Step: Ki67’s Long Road to Respectability. Journal of Clinical Oncology, 2017, 35, 1031-1032.   | 1.6  | 6         |
| 64 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 2017, 35, 2875-2884.   | 1.6  | 1,105     |
| 65 | MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Journal of Clinical Oncology, 2017, 35, 1000-1000.   | 1.6  | 10        |
| 66 | Collective Wisdom: Lobular Carcinoma of the Breast. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 18-21.  | 3.8  | 27        |
| 67 | Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. Journal of Oncology Practice, 2016, 12, e697-e709.                | 2.5  | 12        |
| 68 | Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure. Journal of Clinical Oncology, 2016, 34, 1021-1023.   | 1.6  | 3         |
| 69 | Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical Radiation Oncology, 2016, 6, e219-e234.   | 2.1  | 132       |
| 70 | Aberrant nocturnal cortisol and disease progression in women with breast cancer. Breast Cancer Research and Treatment, 2016, 158, 43-50.   | 2.5  | 25        |
| 71 | Curing Metastatic Breast Cancer. Journal of Oncology Practice, 2016, 12, 6-10.   | 2.5  | 60        |
| 72 | Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.   | 17.5 | 837       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Genome wide association study for anthracycline-induced congestive heart failure.. Journal of Clinical Oncology, 2016, 34, 1017-1017.   | 1.6  | 2         |
| 74 | Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2507-2507. | 1.6  | 3         |
| 75 | A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.. Journal of Clinical Oncology, 2016, 34, 546-546.                 | 1.6  | 2         |
| 76 | Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.. Journal of Clinical Oncology, 2016, 34, e20500-e20500.   | 1.6  | 1         |
| 77 | Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget, 2016, 7, 82244-82253.  | 1.8  | 35        |
| 78 | Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1010-1010.   | 1.6  | 0         |
| 79 | Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.. Journal of Clinical Oncology, 2016, 34, 1026-1026.  | 1.6  | 0         |
| 80 | Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2015, 33, 701-708.                          | 1.6  | 171       |
| 81 | Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clinical Cancer Research, 2015, 21, 5082-5091.   | 7.0  | 106       |
| 82 | Anti-VEGF Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?. Journal of Clinical Oncology, 2015, 33, 133-135.   | 1.6  | 44        |
| 83 | Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2353-2360.   | 1.6  | 167       |
| 84 | Vertical Inhibition of HER2 Yields Horizontal Gains in the Clinic. Clinical Cancer Research, 2015, 21, 2663-2665.   | 7.0  | 2         |
| 85 | Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). British Journal of Cancer, 2015, 113, 1651-1657.   | 6.4  | 43        |
| 86 | Improving the quality of cancer care in America through health information technology. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 772-775.   | 4.4  | 15        |
| 87 | Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.          | 1.6  | 771       |
| 88 | Successes, toxicities and challenges in solid tumours. Nature Reviews Clinical Oncology, 2014, 11, 627-628.   | 27.6 | 23        |
| 89 | Past, Present, and Future Challenges in Breast Cancer Treatment. Journal of Clinical Oncology, 2014, 32, 1979-1986.   | 1.6  | 180       |
| 90 | ASCO's Approach to a Learning Health Care System in Oncology. Journal of Oncology Practice, 2013, 9, 145-148.   | 2.5  | 48        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 91 | CancerLinQ and the Future of Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 430-434.  | 3.8 | 40        |
| 92 | Advances in HER2-positive breast cancer. Clinical Advances in Hematology and Oncology, 2008, 6, 98-100.  | 0.3 | 3         |
| 93 | A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. Journal of Clinical Epidemiology, 2004, 57, 898-910. | 5.0 | 321       |
| 94 | Reply to B. UlaÅ Kahya et al and A. Soran et al. Journal of Clinical Oncology, 0, , .   | 1.6 | 3         |